Clinical Effectiveness of Quetiapine in Children and Adolescents with Tourette's Syndrome

Mazlum Copur1; Baki Arpaci2; Turkay Demir1; Halis Narin3

Disclosures

Clin Drug Invest. 2007;27(2):123-130. 

In This Article

Results

We studied the hospital files of 12 patients meeting the DSM-IV diagnostic criteria for Tourette's syndrome. The mean age of the patients was 12.2 ± 2.7 years (range 9-17 years) and the male:female ratio was 11:1. Table 1 shows the patients' characteristics at baseline.

The initial dose of quetiapine was 25 mg/day; this was increased depending on patient tolerability and efficacy. At weeks 4 and 8, the mean quetiapine dosages were 114.6 ± 51.6 mg/day and 175.0 ± 116.8 mg/day, respectively.

Evaluation of the Y-BOCS scores of 12 patients revealed that obsessive thoughts and/or compulsive behaviours did not interfere with their social or work performance and that these thoughts and behaviours were completely under control.

A total of six patients had ADHD; the other six had no psychiatric disorders. Only two patients were taking carbamazepine (750 mg/day), and a total of three patients had taken risperidone and haloperidol previously. The CTRS-28 (rated by teachers) and the ADHD score (rated by parents) were 32.5 ± 11.7 and 44.4 ± 12.2, respectively. Routine laboratory parameters and serum prolactin levels were normal and did not change throughout the treatment.

Bodyweight and body mass index (BMI) showed a tendency to increase during treatment. At baseline, the mean ± SD bodyweight was 46.2 ± 11.6kg and the mean BMI was 19.1 ± 3.0 kg/m2. At week 4, these parameters increased to 47.6 ± 12.2kg (p < 0.010) and 19.7 ± 3.0 kg/m2(p < 0.016), respectively. At week 8, the mean bodyweight was 48.3 ± 12.9kg (p < 0.016) and the mean BMI was 19.7 ± 3.1 kg/m2 (p < 0.050). These data indicate a gain of approximately 3% in both bodyweight and BMI from baseline values ( Table 2 ).

The baseline total YGTSS score, which was 21.6 ± 4.0 before treatment, showed significant reductions at weeks 4 and 8 of the treatment period, i.e. 65.3% (7.5 ± 4.0) and 74.1% (5.6 ± 8.1), respectively [p < 0.003]. The baseline motor and phonic tic scores and the percentage improvements during the course of quetiapine treatment are shown in Table 3 .

During the course of treatment, there were no reports of adverse effects such as mild rash, diminished sexual desire, erectile dysfunction and headache, which would cause discontinuation of therapy.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....